Edap Tms (NASDAQ:EDAP – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Monday.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price target on shares of Edap Tms in a research report on Thursday, August 29th.
View Our Latest Stock Analysis on EDAP
Edap Tms Stock Up 1.3 %
Edap Tms (NASDAQ:EDAP – Get Free Report) last released its quarterly earnings results on Wednesday, August 28th. The medical equipment provider reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.04). The firm had revenue of $16.97 million during the quarter, compared to the consensus estimate of $17.16 million. Edap Tms had a negative net margin of 34.92% and a negative return on equity of 44.21%. As a group, research analysts predict that Edap Tms will post -0.6 EPS for the current year.
Institutional Investors Weigh In On Edap Tms
Several hedge funds and other institutional investors have recently modified their holdings of EDAP. Commonwealth Equity Services LLC boosted its holdings in Edap Tms by 5.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 71,260 shares of the medical equipment provider’s stock valued at $388,000 after purchasing an additional 4,000 shares during the period. BNP Paribas Financial Markets grew its position in Edap Tms by 23.7% during the third quarter. BNP Paribas Financial Markets now owns 23,000 shares of the medical equipment provider’s stock worth $59,000 after buying an additional 4,400 shares in the last quarter. Orion Capital Management LLC grew its position in Edap Tms by 10.4% during the third quarter. Orion Capital Management LLC now owns 69,800 shares of the medical equipment provider’s stock worth $178,000 after buying an additional 6,600 shares in the last quarter. Virtu Financial LLC bought a new position in Edap Tms during the first quarter valued at about $82,000. Finally, Redhawk Wealth Advisors Inc. acquired a new position in Edap Tms in the 3rd quarter valued at approximately $36,000. Institutional investors and hedge funds own 62.74% of the company’s stock.
About Edap Tms
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments.
See Also
- Five stocks we like better than Edap Tms
- The Risks of Owning Bonds
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- What Are Trending Stocks? Trending Stocks Explained
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- What is the Australian Securities Exchange (ASX)
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.